CHICAGO -- Omitting lymphadenectomy in patients with advanced epithelial ovarian cancer treated with primary or interval cytoreductive surgery after neoadjuvant chemotherapy did not compromise ...

Whether extended lymphadenectomy is associated with improved disease-free and overall survival, as compared with standard lymphadenectomy, among patients with localized muscle-invasive bladder cancer ...

Please provide your email address to receive an email when new articles are posted on . Extended lymphadenectomy did not improve outcomes in localized muscle-invasive bladder cancer vs. standard ...

The SWOG S1011 randomized phase 3 trial found no significant improvement in disease-free or overall survival but a higher rate of grade 3-4 adverse events and an increased risk of death in the 90 days ...

The SWOG S1011 randomized phase 3 trial found no significant improvement in disease-free or overall survival but a higher rate of grade 3-4 adverse events and an increased risk of death in the 90 days ...

Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR ...

Researchers found that adding retroperitoneal lymphadenectomy to cytoreductive surgery did not improve survival among patients with advanced ovarian cancer. The addition of retroperitoneal ...

Current evidence on the safety and efficacy of endoscopic radical inguinal lymphadenectomy is inadequate in quantity. Therefore, this procedure should only be used with special arrangements for ...

A total of 523 patients were randomized between July 1995 and April 2001. Postoperative complications were reported in 24.5% of all patients. Although the morbidity for the extended surgery group ...